This trial will study the safety and effectiveness of a new drug given with an existing drug to find the best dose for treating cancer.
- Multiple Myeloma
3 Primary · 30 Secondary · Reporting Duration: Up to 60 months
Awards & Highlights
3 Treatment Groups
Phase 1 Dose Escalation
1 of 3
Phase 2a Dose Finding: Modakafusp Alfa (DL1) + Daratumumab
1 of 3
Phase 2a Dose Finding: Modakafusp Alfa (DL2) + Daratumumab
1 of 3
58 Total Participants · 3 Treatment Groups
Primary Treatment: Phase 1 Dose Escalation · No Placebo Group · Phase 1 & 2
Who is running the clinical trial?
Age 18+ · All Participants · 0 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Are there current openings for this clinical trial?
"As confirmed by clinicaltrials.gov, this experiment has been actively recruiting since its publication on the 3rd of January 2023 with last edit occuring on December 23 2022." - Anonymous Online Contributor
What is the total sample size of this clinical research?
"To move forward with this medical trial, 58 patients need to be enrolled that meet the predetermined inclusion criteria. Potential participants can register from Cedars-Sinai Medical Center in Los Angeles or James R Berenson, MD Inc. located in West Hollywood." - Anonymous Online Contributor
In what number of health care facilities is this experiment currently being conducted?
"This trial is enrolling patients in Cedars-Sinai Medical Center, James R Berenson MD Inc., and Fort Wayne Medical Oncology & Hematology Inc. as well as 17 additional sites." - Anonymous Online Contributor